Standard Biotools (LAB) Cash from Financing Activities (2010 - 2026)

Standard Biotools (LAB) has reported Cash from Financing Activities for 17 consecutive years, with -$138000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 227.78% year-over-year to -$138000.0 in Q2 2026; TTM through Jun 2026 was $330000.0, a 100.61% increase from a year earlier, with the FY2025 full-year figure at $570000.0, up 100.56% from the prior year.
• Cash from Financing Activities was -$138000.0 for Q2 2026 at Standard Biotools, down from -$40000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $213.0 million in Q2 2022 and troughed at -$54.5 million in Q4 2024.
• A 5-year average of $6.8 million and a median of -$125000.0 in 2025 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities jumped 18474.29% in 2022 and sank 23180.0% in 2023, its largest moves.
• Over 5 years, Cash from Financing Activities stood at -$270000.0 in 2022, then plunged by 271.48% to -$1.0 million in 2023, then tumbled by 5335.69% to -$54.5 million in 2024, then soared by 101.14% to $620000.0 in 2025, then tumbled by 122.26% to -$138000.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$138000.0 (Q2 2026), -$40000.0 (Q1 2026), and $620000.0 (Q4 2025), per Business Quant data.